Logo.png
New Data and Forecasts for the U.S. Skin Cancer Market Strongly Support the Commercial Opportunity for Biofrontera’s Ameluz®
May 24, 2022 11:29 ET | Biofrontera Inc.
WOBURN, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, views new data on skin...
Axim-Sapphire_Logo_-04 (1).png
AXIM Biotechnologies Completes Optimization of Only FDA-Cleared IgE Rapid Diagnostics Test – In-House Manufacturing Lowers Cost and Eliminates Supply Chain Expenditures
May 24, 2022 09:00 ET | AXIM BIOTECHNOLOGIES, INC
SAN DIEGO, May 24, 2022 (GLOBE NEWSWIRE) -- AXIM Biotechnologies, Inc (OTCQB: AXIM) (“AXIM Biotech,” “AXIM” or “the Company”), an international healthcare solutions company targeting ocular surface...
Synlogic_Logo_Blue.png
Synlogic Receives Positive Opinion on Orphan Designation from the European Medicines Agency for SYNB1618 for the Treatment of Phenylketonuria
May 24, 2022 07:00 ET | Synlogic, Inc.
CAMBRIDGE, Mass., May 24, 2022 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), a clinical-stage biotechnology company developing medicines for metabolic and immunological diseases through its...
Pfizer-BioNTech COVID-19 Vaccine Demonstrates Strong Immune Response, High Efficacy and Favorable Safety in Children 6 Months to Under 5 Years of Age Following Third Dose
May 23, 2022 06:45 ET | BioNTech SE
Based on topline data, three doses of the Pfizer-BioNTech COVID-19 Vaccine met all immunobridging criteria required for Emergency Use AuthorizationThe third 3-µg dose was well-tolerated among 1,678...
Pfizer-BioNTech COVID-19-Impfstoff zeigt bei Kindern im Alter von 6 Monaten bis unter 5 Jahren nach drei Dosen starke Immunantworten, hohe Wirksamkeit und vorteilhaftes Sicherheitsprofil
May 23, 2022 06:45 ET | BioNTech SE
Basierend auf den ersten Studiendaten erfüllen drei Dosen des Pfizer-BioNTech COVID-19-Impfstoffs alle für die US-Notfallzulassung notwendigen Immunobridging-Kriterien (Vergleich der...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, RESPECTED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
May 20, 2022 13:53 ET | The Rosen Law Firm PA
NEW YORK, May 20, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Axsome...
logo.jpg
Vallon Pharmaceuticals Reports Additional Pharmacokinetic and Pharmacodynamic Data from SEAL Study of ADAIR
May 12, 2022 08:30 ET | Vallon Pharmaceuticals Inc.
PHILADELPHIA, PA, May 12, 2022 (GLOBE NEWSWIRE) -- Vallon Pharmaceuticals, Inc. (NASDAQ: VLON), (“Vallon” or the “Company”), a clinical-stage biopharmaceutical company primarily focused on the...
CVRX_Outsmart the heart_Logo_RGB Blue.png
CVRx® Receives MR-Conditional Labeling Approval for its Barostim™ Heart Failure System
May 09, 2022 08:30 ET | CVRx, Inc.
Heart failure patients implanted with Barostim can now receive conditional MRI scans MINNEAPOLIS, May 09, 2022 (GLOBE NEWSWIRE) --  CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), developer of the world’s...
22nd Century Group logo.jpg
22nd Century Group (Nasdaq: XXII) Reports Business Highlights and Financial Results for the First Quarter 2022
May 05, 2022 06:00 ET | 22nd Century Group, Inc
Launched VLN® Pilot Program in Chicago with Circle K as First Retail Trade PartnerBegan VLN® Shipments to South Korea for First International LaunchFDA’s Proposed Menthol Ban Could Leave VLN® Menthol...
July 30, 2021 - ROSEN LOGO.jpg
ROSEN, A LEADING LAW FIRM, Encourages AbbVie Inc. Investors With Losses to Secure Counsel Before Important Deadline in Securities Class Action – ABBV
May 04, 2022 16:53 ET | The Rosen Law Firm PA
NEW YORK, May 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of AbbVie Inc. (NYSE: ABBV) between April 30, 2021 and August...